Abstract

Endometrial cancer, traditionally affecting postmenopausal women, is increasingly diagnosed in younger women, necessitating fertility-preserving strategies. Progestin-based therapies, such as levonorgestrel intrauterine devices (IUDs) and oral medroxyprogesterone, offer viable alternatives to hysterectomy for early-stage, low-grade disease. This article reviews the efficacy, safety, and challenges of fertility-sparing treatments, synthesizing clinical data and discussing long-term outcomes. Results indicate high response rates, with 70% of patients achieving complete remission, though recurrence risk persists. Future directions include optimizing patient selection and integrating molecular profiling to enhance outcomes.